文献速递肝病消化道肿瘤与早癌

每日阿司匹林治疗与慢性丙型肝炎患者肝细胞癌风险的关联

Association of Daily Aspirin Therapy With Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis C Virus Infection.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-04-28

基于台湾全民健康保险研究数据库的队列研究,筛选237,963例慢性HCV感染者,将连续每日服用阿司匹林≥90天的2,478例与倾向评分1:2匹配的4,956例从未抗血小板治疗者比较。5年HCC累积发生率阿司匹林组显著低于未治疗组(4.67% vs 7.32%,P<.001),多变量分析显示阿司匹林与HCC风险降低独立相关(HR 0.78,95%CI 0.64-0.95,P=.011)。

要点

  • 每日阿司匹林治疗与慢性HCV感染者HCC风险降低独立相关(HR 0.78)。
  • 阿司匹林组5年HCC累积发生率为4.67%,低于未治疗组的7.32%。
  • 高龄、男性和肝硬化是HCC风险增加的独立因素。

核心结论

  • 在台湾全国性队列中,每日阿司匹林治疗与HCV相关HCC风险显著降低相关。

研究设计与样本

  • 基于台湾全民健康保险研究数据库的队列研究,1997至2011年筛选237,963例慢性HCV感染者。
  • 连续每日服用阿司匹林≥90天的2,478例为治疗组,按倾向评分1:2匹配4,956例从未抗血小板治疗者为对照组。
  • 以死亡为竞争风险事件调整后分析HCC累积发生率和风险比(HR)。

主要发现

  • 治疗组5年HCC累积发生率为4.67%(95%CI 3.74%-5.59%),未治疗组为7.32%(95%CI 6.33%-8.30%),P<.001。
  • 多变量回归分析中,阿司匹林治疗与HCC风险降低独立相关(HR 0.78,95%CI 0.64-0.95,P=.011)。
  • 敏感性亚组分析均验证该关联(所有HR<1.0)。
  • 年龄每增加1岁(HR 1.03,95%CI 1.02-1.04)、男性(HR 1.46,95%CI 1.21-1.77)和肝硬化(HR 3.13,95%CI 2.55-3.84)与HCC风险增加独立相关。

临床怎么用

  • 对于慢性HCV感染者,每日阿司匹林治疗可能与HCC风险降低相关,但需结合个体出血风险等综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Aspirin therapy has been associated with reduced risk of colon cancer, but there is only limited evidence for its effects on risk of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). We aimed to investigate the association of daily aspirin therapy with HCV-related HCC risk. METHODS: In this cohort study, based on Taiwan's National Health Insurance Research Database, we screened 237,963 patients with chronic HCV infection for the period of 1997 through 2011. We excluded patients with confounding conditions and 2478 patients who continuously received daily aspirin therapy for 90 days or more (treated group) were randomly matched 1:2 with 4956 patients who had never received antiplatelet therapy (untreated group) by means of propensity scores. Cumulative incidence of, and hazard ratio (HR) for, HCC development were analyzed after we adjusted for patient mortality as a competing risk event. RESULTS: The cumulative incidence of HCC in the treated group was significantly lower than that in the untreated group over 5 years (4.67%; 95% CI, 3.74%-5.59% vs 7.32%; 95% CI, 6.33%-8.30%; P<.001). In the multivariable regression analysis, aspirin therapy was independently associated with a reduced HCC risk (HR, 0.78, 95% CI, 0.64-0.95; P = .011), after adjustment for age per year, male sex, cirrhosis, liver decompensation, hyperlipidemia, statin use, and interferon therapy. Sensitivity subgroup analyses also verified this association (all HRs<1.0). In addition, older age (HR, 1.03 per year; 95% CI, 1.02-1.04), male sex (HR, 1.46; 95% CI, 1.21-1.77), and cirrhosis (HR, 3.13; 95% CI, 2.55-3.84) were independently associated with an increased HCC risk. CONCLUSIONS: In a nationwide cohort study in Taiwan, we found aspirin therapy to be significantly associated with a reduced risk of HCV-related HCC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lee TY, Hsu YC, Tseng HC, et al. Association of Daily Aspirin Therapy With Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis C Virus Infection. Clin Gastroenterol Hepatol. 2020. PMID: 32360983. doi:10.1016/j.cgh.2020.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。